Autonomix Medical, Inc. (NASDAQ:AMIX)
| Market Cap | $484.14K-96.1% |
| Revenue (ttm) | $0 |
| Net Income | -$11.78M+29.4% |
| EPS | -$20.09+81.6% |
| Shares Out | 543.30K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,177 |
| Open | $1.02 |
| Previous Close | $1.04 |
| Day's Range | $0.88 - $1.02 |
| 52-Week Range | $0.88 - $24.68 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 10, 2027 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Next catalysts
- Feb 10, 2027Earnings report
$AMIX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AMIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AMIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AMIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AMIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AMIX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AMIX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Autonomix received new US patent for proprietary catheter-based sensing technology and highlighted renal denervation strategy at major medical conference.
